Dimensional Fund Advisors LP Boosts Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Dimensional Fund Advisors LP lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) by 48.5% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 936,516 shares of the company’s stock after acquiring an additional 305,819 shares during the period. Dimensional Fund Advisors LP owned approximately 1.07% of Revolution Medicines worth $18,468,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Bessemer Group Inc. grew its stake in shares of Revolution Medicines by 8.9% during the third quarter. Bessemer Group Inc. now owns 476,850 shares of the company’s stock worth $9,404,000 after acquiring an additional 38,796 shares during the last quarter. Amalgamated Bank grew its stake in shares of Revolution Medicines by 20.2% during the third quarter. Amalgamated Bank now owns 9,965 shares of the company’s stock worth $197,000 after acquiring an additional 1,673 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Revolution Medicines by 17.3% during the third quarter. New York State Common Retirement Fund now owns 50,130 shares of the company’s stock worth $989,000 after acquiring an additional 7,391 shares during the last quarter. TD Asset Management Inc. grew its stake in shares of Revolution Medicines by 17.3% during the third quarter. TD Asset Management Inc. now owns 94,173 shares of the company’s stock worth $1,841,000 after acquiring an additional 13,876 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Revolution Medicines by 36.1% during the third quarter. Arizona State Retirement System now owns 16,311 shares of the company’s stock worth $322,000 after acquiring an additional 4,329 shares during the last quarter.

Revolution Medicines Trading Down 1.4 %

Shares of NASDAQ:RVMD opened at $24.59 on Wednesday. Revolution Medicines, Inc. has a 12-month low of $14.08 and a 12-month high of $31.37. The company has a market capitalization of $2.23 billion, a PE ratio of -7.93 and a beta of 1.49. The business has a 50 day moving average of $25.71 and a two-hundred day moving average of $22.63.

Revolution Medicines (NASDAQ:RVMD – Get Rating) last announced its quarterly earnings results on Monday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.21. The company had revenue of $15.33 million during the quarter, compared to the consensus estimate of $6.75 million. Revolution Medicines had a negative return on equity of 41.17% and a negative net margin of 702.95%. Equities research analysts predict that Revolution Medicines, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RVMD has been the topic of a number of recent research reports. Needham & Company LLC upped their target price on Revolution Medicines from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Tuesday, February 28th. Guggenheim reiterated a “buy” rating and issued a $38.00 target price on shares of Revolution Medicines in a research report on Tuesday, February 28th. Oppenheimer upped their target price on Revolution Medicines from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Tuesday, February 28th. The Goldman Sachs Group upped their target price on Revolution Medicines from $20.00 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, March 1st. Finally, HC Wainwright upped their target price on Revolution Medicines from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, December 8th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines has an average rating of “Moderate Buy” and an average target price of $32.25.

Revolution Medicines Company Profile

(Get Rating)

Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.